TBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Theravance Biopharma is: High Risk: High uncertainty.
For the Biotechnology subindustry, Theravance Biopharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Risk Assessment falls into.
Theravance Biopharma (NAS:TBPH) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Theravance Biopharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Rhonda Farnum | officer: SVP, Comm & Medical Affairs | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Richard A Graham | officer: SVP, Development | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kelly James Connor | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Susannah Gray | director | 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121 |
Brett A. Grimaud | officer: SVP, Gen Counsel and Secretary | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Aziz Sawaf | officer: SVP & Chief Financial Officer | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Rick E Winningham | director, officer: Chief Executive Officer | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Andrew A. Hindman | officer: SVP, Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Eli Samaha | 10 percent owner | ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007 |
Wam Gp Llc | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Andrew M Weiss | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Weiss Asset Management Lp | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Philip D Worboys | officer: SVP, Translational Science | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Brett K Haumann | officer: VP-Clinical Develop. | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
From GuruFocus
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 11-18-2022
By PRNewswire • 12-18-2023
By PRNewswire • 10-19-2023
By PRNewswire PRNewswire • 04-24-2023
By PRNewswire PRNewswire • 01-09-2023
By PRNewswire • 08-07-2023
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 06-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.